| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.07 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.07 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.061 | 0.07 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.064 | 0.08 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.08 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.081 | 0.08 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.14 | 0.08 |
| mRNA | Vinorelbine | GDSC1000 | pan-cancer | AAC | 0.061 | 0.09 |